Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

3 1 1 1

What is this study about?

This clinical trial evaluates the immune response to Bexsero, a vaccine against invasive meningococcal disease caused by group B bacteria. The study focuses on individuals aged 10 to 20 years who previously received this vaccine in early childhood. Meningococcal disease is a serious infection that can cause inflammation of the membranes surrounding the brain and spinal cord.

The vaccine is given as a suspension for intramuscular injection using a pre-filled syringe. Each participant will receive one dose of 0.5 milliliters of the vaccine. The study compares the immune response between people who received the vaccine in early childhood and those who have never received it before.

The main purpose is to determine if people previously vaccinated with Bexsero show a stronger immune response to a booster dose compared to those receiving the vaccine for the first time. The study will monitor participants for 31 days after vaccination to assess both the immune response and safety of the vaccine.

1 Initial vaccination visit (Day 1)

You will receive a Bexsero vaccine through an injection in your muscle.

If you are a female of childbearing age, a pregnancy test will be performed.

Blood samples will be collected to measure your immunity levels against meningococcal B bacteria.

You will receive a diary to record any reactions at the injection site or other symptoms for the next 7 days.

2 7-day monitoring period

Record any injection site reactions (such as pain, redness, or swelling) in your diary.

Document any general symptoms like fever, headache, or muscle pain.

Note any other health changes you experience.

3 Follow-up visit (Day 31)

Return to the study site for a final visit.

Blood samples will be collected to measure your immunity levels against meningococcal B bacteria.

The study team will review your diary and any health changes you experienced.

This visit concludes your participation in the study.

4 Safety monitoring

The study team will monitor for any serious health events throughout the entire study period.

Special attention will be paid to monitoring for arthritis as a specific safety concern.

Any significant health events will be followed up until resolved.

Who Can Join the Study?

Age requirement: Must be between 10 and 20 years old at the time of first study treatment
Previous vaccination status must be either:
- Previously received meningococcal B vaccine in early childhood (with documented proof), or
- Never received any meningococcal B vaccine (with documented proof)
Must be able to follow study requirements and attend follow-up visits
Must provide written informed consent:
- Ages 10-16: Both parent/guardian and participant must provide consent
- Ages 16/18-20: Participant can provide consent independently
For female participants:
- Can participate if not able to bear children (before first menstrual period, surgical procedures preventing pregnancy), or
- If able to bear children, must:
  - Use effective birth control for 1 month before study
  - Have negative pregnancy test before treatment
  - Agree to continue birth control throughout study
Must have proper documentation of vaccination history (electronic or paper records)

Who Cannot Join the Study?

History of meningococcal disease (an infection that causes inflammation of the protective membranes covering the brain and spinal cord)
Previous severe allergic reaction to any vaccine components
Currently participating in another clinical trial
Any serious chronic medical condition that could interfere with the study
Received any vaccine within 30 days before the study
Current fever or acute illness
Pregnancy or breastfeeding
Known or suspected immune system disorders
History of seizures or neurological conditions
Blood clotting disorders or regular use of blood thinners
Taking medications that affect the immune system
History of fainting with vaccine administration
Unable to complete all required study visits
Any condition that, in the opinion of the study doctor, would make participation unsafe

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Rokotetutkimuskeskus Finvac Oy	Tampere	Finland
Instituto Hispalense De Pediatria S.L.	Sevilla	Spain

Other Sites

Site Name	City	Country
Azienda Ospedaliera Universitaria Meyer IRCCS	Florence	Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico	Milan	Italy
IRCCS Ospedale Policlinico San Martino	Genoa	Italy
Universidade De Santiago De Compostela	Santiago De Compostela	Spain
Azienda Ospedaliero-Universitaria Maggiore Della Carita	Novara	Italy

Trial status

Country	Status	Recruitment Start
Finland	Not recruiting	20.08.2025
Italy	Not recruiting	20.08.2025
Spain	Not recruiting	20.08.2025

Trial locations

Investigated drugs:

rMenB+OMV NZ is a vaccine designed to protect against meningococcal group B disease, which is a serious bacterial infection that can cause meningitis and blood poisoning. This vaccine contains proteins from meningococcal bacteria combined with outer membrane vesicles (OMV) from New Zealand strain. It helps the body’s immune system recognize and fight against the bacteria that cause meningococcal B disease. The vaccine is given as an injection and works by stimulating the immune system to produce antibodies against the bacteria.

Investigated diseases:

Meningococcal infection

Invasive Meningococcal Disease (IMD) – A bacterial infection caused by Neisseria meningitidis that can spread through the bloodstream and affect various organs. The disease typically begins with flu-like symptoms, including fever, headache, and neck stiffness. As the infection progresses, it can cause inflammation of the membranes surrounding the brain and spinal cord. The condition can develop rapidly, sometimes within hours, and may be accompanied by a distinctive rash. IMD can affect people of any age, though it occurs more frequently in young children and adolescents.

Trial ID:

2024-519549-31-00

Protocol code:

220030

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?